Edwin Snape, vice-chairman of Deltex Medical, has trousered nearly £1m from the sale of shares in the company, cashing in on a surge last month following some well-received news.
He offloaded almost 3.4m shares at 28.5p a time, but kept just over 1m shares, which is about 0.75% of the company.
Shares in Deltex Medical shot up after it said its CardioQ-ODM oesophageal monitor has been recommended by the National Institute for Clinical Excellence (NICE) for use in patients undergoing major surgery.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
NICE's recommendation now applies to 837,000 surgical patients a year in the NHS in England alone, it estimates.
The shares have risen sharply since December, when Snape took about 31,000 shares at 19.5p a time as part of an agreement to receive shares instead of cash remuneration.
Deltex also announced today that following his big sale he immediately started rebuilding his stake, receiving 21,053 shares at 28.5p as part of the same agreement.
-
Is investing in AIM still worth it after IHT clampdown?HMRC expects to rake in £110 million a year from upcoming inheritance tax changes on AIM shares. The tax relief will be cut from April 2026, meaning you could find yourself paying 20% in inheritance tax.
-
AI in finance: how is technology changing financial advice?There are huge opportunities for AI to improve and democratise financial services, particularly financial advice. But is the regulatory environment ready for AI to become mainstream in finance?
